Open AccessEffect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock
Author(s) -
PierreFrançois Laterre,
Scott Berry,
Allan Blemings,
Jan E. Carlsen,
Bruno François,
Todd Graves,
Karsten Jacobsen,
Roger Lewis,
Steven M. Opal,
Anders Perner,
Peter Pickkers,
James A. Russell,
Nis A. Windeløv,
Donald M. Yealy,
Pierre Asfar,
Morten H. Bestle,
Grégoire Müller,
Cédric Bruel,
N. Brulé,
Johan Decruyenaere,
A. Dive,
Thierry Dugernier,
Kenneth Krell,
JeanYves Lefrant,
Bruno Mégarbane,
Emmanuelle Mercier,
JeanPaul Mira,
JeanPierre Quenot,
Bodil Steen Rasmussen,
HansChristian ThorsenMeyer,
Margot Vander Laenen,
Marianne Vang,
Philippe Vig,
Isabelle Vinatier,
Sine Wichmann,
Xavier Wittebole,
Anne Louise Kjølbye,
Derek C. Angus,
for the SEPSIS-ACT Investigators
Publication year - 2019
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2019.14607
Subject(s) - medicine , septic shock , anesthesia , placebo , adverse effect , clinical endpoint , randomization , sepsis , randomized controlled trial , regimen , alternative medicine , pathology
Norepinephrine, the first-line vasopressor for septic shock, is not always effective and has important catecholaminergic adverse effects. Selepressin, a selective vasopressin V1a receptor agonist, is a noncatecholaminergic vasopressor that may mitigate sepsis-induced vasodilatation, vascular leakage, and edema, with fewer adverse effects.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom